UK's medicine regulator said on Monday it has temporarily restricted the use of French vaccine maker Valneva's shot to treat ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Results from the Phase II VLA1553-221 trial show that a full dose of Ixchiq demonstrated a 96.5% seroresponse rate in ...

The UK’s Medicines and Healthcare products Regulatory Agency said that following global reports of serious adverse events in ...

Diana Moser has, to the best of her knowledge, not contracted Lyme disease, a welcome status quo that might be credited to ...

GSK has licensed its shigella vaccine candidate to Bharat Biotech. The Big Pharma, which has vowed to help Bharat with trial ...

Financial disclosure records show that members of the vaccine safety panel fired by HHS Secretary RFK Jr. had financial ties to the pharmaceutical industry.

Following global reports of serious adverse events in older people, the government’s independent expert advisory body, the UK ...

The MHRA is working with the manufacturer of the IXCHIQ  vaccine, Valneva. This vaccine was approved by the MHRA in February 2025. There will be no impact on operational issues as this vaccine is not ...

Pfizer has acquired an 8.1% stake in French vaccines developer Valneva at a cost of €90.5 million (around $95 million) and rejigged the terms of their alliance to develop a shot for Lyme disease.